## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ara-290-carpal-tunnel`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ara-290-carpal-tunnel` v21 · content_hash `da6f71a818af102f…` · thread_head genesis · 31 DIVs
- **thesis (c2):** Subgroup with low baseline corneal nerve density showed significant CNFD increase after ARA-290 vs placebo.
  - c16 [human/active] Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
  - c17 [human/active] There is a lack of large randomized human trials for ARA-290's common marketed uses, including its application in carpal tunnel syndrome.
  - c20 [human/active] It is unknown whether the effects of ARA-290 on nerve symptoms and fiber density in patients with neuropathy can be directly extrapolated to carpal tunnel syndr
  - c23 [human/active] ARA-290 is a nonerythropoietic peptide derived from erythropoietin, proposed to act by targeting the innate repair receptor to treat neuropathy.
  - c24 [human/active] The long-term efficacy and safety of ARA-290 for chronic neuropathic conditions, such as carpal tunnel syndrome, are not established due to the limited duration
  - c3 [human/active] No human trials of ARA-290 in carpal tunnel syndrome exist.
  - c27 [preclinical/active] 2025 preclinical study showing ARA290 (cibinetide) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting nerve repair 
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ara-290-carpal-tunnel`
- **title:** ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density
- **url:** https://miscsubjects.com/a/ara-290-carpal-tunnel
- **register:** source_ledger
- **updated:** 2026-07-17T02:38:09.221Z
- **tags:** peptide, topic

## Body

## Regeneration vs degeneration — where this fits
Nerves can break down after compression or injury. Carpal tunnel involves pressure on the median nerve. If breakdown outruns repair, symptoms persist. ARA-290 is studied for nerve repair pathways rather than symptom suppression.

## What it is
ARA-290 is a peptide derived from erythropoietin. It does not raise red blood cells. It targets the innate repair receptor.

## How it works
Step 1: The peptide binds the innate repair receptor.  
Step 2: Binding activates repair signals in nerve tissue.  
Step 3: Signals support nerve fiber maintenance and symptom change in some models.

## Why it would work (logic chain)
If the receptor controls repair, then binding it may increase nerve fiber density. If density increases, then symptoms tied to low density may decrease. If symptoms decrease without addressing mechanical compression, then benefit may stay limited in entrapment cases.

## Why people take it
People take it when they seek nerve repair options beyond standard symptom relief. Some have carpal tunnel confirmed by EMG. Some have other neuropathies.

## How many people take it
Unknown. The ledger records nine sources total. No population count exists.

## Evidence inventory
Sources total: 9.  
Human studies: 1.  
Animal studies: 1 (via review).  
Anecdotal sources: 7 (5 Reddit, 2 X).  
Claims human: 4.  
Claims preclinical: 4.  
Claims anecdotal: 9.

## What scientists say
One phase 2 human trial in type 2 diabetes patients with neuropathy gave 4 mg daily for 28 days (source s1). Neuropathic symptoms on PainDetect improved in the ARA-290 group. Corneal nerve fiber density rose by +2.6 ± 1.0 fibers/mm² in the treatment subgroup (n=18, p=0.02). A linear link appeared between density change and symptom change.  

A review notes rat data where ARA-290 gave long-lasting neuropathic pain relief (source s2).  

No human trial of ARA-290 in carpal tunnel exists (claim c3). Effects seen in diabetic neuropathy may not transfer to compression neuropathy (claim c20).

## What people say on Reddit
One user with tarsal tunnel (analogous to carpal tunnel) reported no benefit for compression pain but noted positive axonal repair in a different injury after two months (source s3).  

Another user stated nerve damage boundaries shrank several inches in weeks and attributed the change to ARA-290 (source s4).  

Multiple users reported painful pins and needles flares at 2–4 mg and stopped early; one linked sensitivity to Sjögren’s (source s5).  

One user with EMG-confirmed carpal tunnel and multi-site neuropathy planned a 28-day cycle at 3–6 mg/day but reported no outcome yet (source s6).  

One post described ARA-290 as a nerve healing peptide for conditions including carpal tunnel and asked for experiences (source s7).

## What people say on X
One user sought results for carpal tunnel use and reported receiving a bad batch with floating clouds (source s8).  

One user with severe work-induced carpal tunnel asked where to buy ARA-290 (source s9).

## What we do not know
No human trials test ARA-290 specifically in carpal tunnel. It is unknown if diabetic neuropathy findings apply to mechanical compression cases. Long-term efficacy and safety data for chronic nerve conditions are absent.

## Safety and limits
The ledger records short-term human data only. Some users reported painful nerve flares leading to early stop. No population safety data exist.

## Claims (25)

- **c26** [mechanistic w=0.3] Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c3** [human w=0.5] No human trials of ARA-290 in carpal tunnel syndrome exist.
  - who_claims: grok/4.3-populate
- **c19** [mechanistic w=0.4] While the claim states that no human trials of ARA-290 in carpal tunnel syndrome exist, this contradicts the information provided in sourced claims c1 and c2, which describe a phase 2 trial involving ARA-290 and human neuropathy.
  - who_claims: kimi/moonshot-v1-8k (adversary)
- **c22** [mechanistic w=0.4] The claim that no human trials of ARA-290 in carpal tunnel syndrome exist is contradicted by sourced claims c1 and c2, which describe a phase 2 trial involving ARA-290 and human neuropathy.
  - who_claims: kimi/moonshot-v1-8k (adversary)
- **c_map_ara-290-carpal-tunnel** [system w=0.35] Combinatorial mapping (transparent): ara-290 vs carpal-tunnel — regen=0.59, degen=0.75, Δ=-0.16. Method: layer_relevance(0.60) × evidence_factor(0.85); catalog.degen_score for Carpal tunnel syndrome.
  - who_claims: grok/4.3-populate
  - slot: what_is_known
- **c25** [system w=0.35] ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
  - who_claims: miscsubjects protocol
  - slot: what_it_is
- **c10** [anecdotal w=0.3] User seeking experiences with ARA-290 specifically for carpal tunnel; reports bad batch purchased but no treatment outcome yet.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s8
- **c11** [anecdotal w=0.3] User with severe work-induced carpal tunnel inquiring about purchasing ARA-290 (no outcome reported).
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s9
- **c18** [anecdotal w=0.3] User reports from anecdotal sources vary widely in their experiences with ARA-290 for carpal tunnel syndrome, with some reporting no benefit and others noting positive effects on nerve repair but not on compression-related pain.
  - who_claims: kimi/moonshot-v1-8k
  - slot: who_claims_what
  - sources: s3, s4, s5, s6, s7, s8, s9
- **c21** [anecdotal w=0.3] Anecdotal reports of ARA-290's effects on carpal tunnel syndrome are limited and vary widely, with no clear consensus on its efficacy.
  - who_claims: kimi/moonshot-v1-8k
  - slot: who_claims_what
  - sources: s3, s4, s5, s6, s7, s8, s9
- **c1** [human w=0.8] In a phase 2 trial of T2D patients with neuropathy, 4 mg ARA-290 daily for 28 days improved PainDetect scores significantly vs placebo.
  - who_claims: grok/4.3-populate
  - slot: what_is_known
  - sources: s1
- **c2** [human w=0.8] Subgroup with low baseline corneal nerve density showed significant CNFD increase after ARA-290 vs placebo.
  - who_claims: grok/4.3-populate
  - slot: what_is_known
  - sources: s1
- **c16** [human w=0.8] Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
  - who_claims: system/protocol
  - slot: disclaimer
- **c17** [human w=0.8] There is a lack of large randomized human trials for ARA-290's common marketed uses, including its application in carpal tunnel syndrome.
  - who_claims: kimi/moonshot-v1-8k
  - slot: what_is_unknown
  - sources: s1
- **c20** [human w=0.8] It is unknown whether the effects of ARA-290 on nerve symptoms and fiber density in patients with neuropathy can be directly extrapolated to carpal tunnel syndrome, as no specific studies have been conducted for this condition.
  - who_claims: kimi/moonshot-v1-8k
  - slot: what_is_unknown
  - sources: s1
- **c23** [human w=0.8] ARA-290 is a nonerythropoietic peptide derived from erythropoietin, proposed to act by targeting the innate repair receptor to treat neuropathy.
  - who_claims: gemini-collaborator
  - slot: what_is_known
  - sources: s1, s2
- **c24** [human w=0.8] The long-term efficacy and safety of ARA-290 for chronic neuropathic conditions, such as carpal tunnel syndrome, are not established due to the limited duration of available human trial data.
  - who_claims: gemini-collaborator
  - slot: what_is_unknown
  - sources: s1
- **c27** [preclinical w=0.5] 2025 preclinical study showing ARA290 (cibinetide) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting nerve repair and regeneration via reduced inflammation and ROS.
  - who_claims: grok-4.3
  - slot: mechanism
  - sources: s10
- **c5** [anecdotal w=0.3] User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair in another nerve injury after 2 months at 5mg/day.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s3
- **c6** [anecdotal w=0.3] Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tunnel pain.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s4
- **c7** [anecdotal w=0.3] Multiple users report bad outcomes with ARA-290 causing painful nerve flares/pins and needles, leading them to stop treatment early despite trying titration for neuropathy (one mentions autoimmune-related sensitivity).
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s5
- **c8** [anecdotal w=0.3] User with confirmed carpal tunnel (via EMG) and other neuropathy planning 28+ day ARA-290 cycle at 3-6mg/day for nerve pain, no outcome reported yet but notes interest in honest results.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s6
- **c9** [anecdotal w=0.3] Post discusses ARA-290 as potential for nerve regeneration including carpal tunnel syndrome, seeking user experiences (no detailed personal outcomes in snippet).
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s7
- **c4** [speculative w=0.12] Rat models show ARA-290 produces long-lasting neuropathic pain relief via repair pathways.
  - who_claims: grok/4.3-populate
  - slot: mechanism
  - sources: s2
- **c12** [speculative w=0.12] Commercial vendors and clinics market this compound (0 commercial/clinic sources catalogued) — marketing material, not evidence.
  - who_claims: commercial vendors
  - slot: who_claims_what

## Voxel graph (25 atoms · 60 edges)
- full graph: https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (10)
- chain valid: yes · head: `3e42ffedd1ae08a2`

### s1 · pubmed · ok
- title: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
- summary: Phase 2 RCT: 4 mg SC daily ×28 d improved symptoms and CNFD in diabetic neuropathy subgroup.
- quote: Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group... In this group, a linear relationship existed between the observed change in CNFD and the change in symptoms... mean change in of +2.6 ± 1.0 fibers/mm² for ARA 290 (n = 18; p = 0.02)
- claim_ids: c1, c2, c17, c20, c23, c24
- hash: `e64b5c5b9b99feda`

### s2 · review · ok
- title: Targeting the innate repair receptor to treat neuropathy
- url: https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx
- summary: Reviews preclinical rat data on neuropathic pain relief.
- quote: Swartjes and colleagues... showed that ARA-290 produced long-lasting relief of neuropathic pain in rats
- claim_ids: c4, c23
- hash: `87b2b0e93471913b`

### s3 · reddit · ok
- title: Anybody try ARA-290 peptide for nerve damage?
- url: https://www.reddit.com/r/Biohackers/comments/1p2887b/anybody_try_ara290_peptide_for_nerve_damage/
- summary: User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair in another nerve injury after 2 months at 5mg/day.
- quote: I also have tarsal tunnel syndrome, which is the ankle version of carpal tunnel syndrome; my tibial nerve is entrapped in scar tissue from a surgery. Because that nerve pain is caused by mechanical compression, I don't expect the peptide to help (and so far it has not).
- claim_ids: c5, c18, c21
- hash: `8a505d8fb61a169c`

### s4 · reddit · ok
- title: Anybody try ARA-290 peptide for nerve damage?
- url: https://www.reddit.com/r/Biohackers/comments/1p2887b/anybody_try_ara290_peptide_for_nerve_damage/
- summary: Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tunnel pain.
- quote: The boundaries of my nerve damage have shrunk several inches! In the first few weeks, it shrunk more than it had in the 6 months between the initial damage and when I started ARA-290. ... I am 100% certain that ARA-290 is responsible for my experience of several inches of recovery in mere weeks after the preceding 6 months of no improvement.
- claim_ids: c6, c18, c21
- hash: `c357ecd533dfadcd`

### s5 · reddit · ok
- title: Peptide ARA-290 : r/neuropathy
- url: https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/
- summary: Multiple users report bad outcomes with ARA-290 causing painful nerve flares/pins and needles, leading them to stop treatment early despite trying titration for neuropathy (one mentions autoimmune-related sensitivity).
- quote: I titrated up 0.5 mg, 1 mg, 2 mg, 3 mg and finally 4 mg. At 3 and 4 milligrams I experienced painful pins and needles in my heels so I had to stop. ... I began last week at .5 mg, then 1, then 2, then 3 and finally 4 mg. I tittered slowly up due to my Sjogren's disease. I quickly developed painful tingling around the outside of both feet at 2 mg. Those last 3 days were very painful. ... I tried ARA290 last October and had to quit after 6 days.
- claim_ids: c7, c18, c21
- hash: `d98046bdd43416e6`

### s6 · reddit · ok
- title: ARA-290 Disc Herniaton & Nerve Pain : r/neuropathy
- url: https://www.reddit.com/r/neuropathy/comments/1tvw5x6/ara290_disc_herniaton_nerve_pain/
- summary: User with confirmed carpal tunnel (via EMG) and other neuropathy planning 28+ day ARA-290 cycle at 3-6mg/day for nerve pain, no outcome reported yet but notes interest in honest results.
- quote: Periphial neuropathy in hands/shoulder (emg showed carpal tunnel and medial nerve damage) feet and legs to lower back (3 fusions, lt knee replacement, rt hip replacement and waiting on rt knee replacement).
- claim_ids: c8, c18, c21
- hash: `cc7b287dc3194fd4`

### s7 · reddit · ok
- title: Anyone try ARA290 peptide for this tinnitus? : r/tinnitus
- url: https://www.reddit.com/r/tinnitus/comments/1papfky/anyone_try_ara290_peptide_for_this_tinnitus/
- summary: Post discusses ARA-290 as potential for nerve regeneration including carpal tunnel syndrome, seeking user experiences (no detailed personal outcomes in snippet).
- quote: It's a nerve healing peptide known to regenerate nerves like sciatica and carpal tunnel syndrome ...
- claim_ids: c9, c18, c21
- hash: `dfdaa03558fae0eb`

### s8 · x · ok
- title: X post by @I_Research_Pept
- url: https://x.com/I_Research_Pept/status/2064434147792470183
- summary: User seeking experiences with ARA-290 specifically for carpal tunnel; reports bad batch purchased but no treatment outcome yet.
- quote: Has anyone out there tried ARA-290? If so, what were you treating and what were the results? I never hear about this peptide, but want to try it for carpal tunnel. I purchased 7 vials from a vendor, but unfortunately, they were bad (floating clouds) and I have not repurchased yet
- claim_ids: c10, c18, c21
- hash: `b79271af5579e569`

### s9 · x · ok
- title: X post by @SEpilogueG
- url: https://x.com/SEpilogueG/status/2049848962459513117
- summary: User with severe work-induced carpal tunnel inquiring about purchasing ARA-290 (no outcome reported).
- quote: Where do I buy these, specifically ARA-290? I have severe work induced carpal tunnel.
- claim_ids: c11, c18, c21
- hash: `4d9806b758576489`

### s10 · pubmed · ok
- title: ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury
- url: https://pubmed.ncbi.nlm.nih.gov/40216181/
- summary: 2025 preclinical study showing ARA290 (cibinetide) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting nerve repair and regeneration via reduced inflammation and ROS.
- quote: EPO and ARA290 promote repair and regeneration by inhibiting the activation of NLRP3 inflammasome after sciatic nerve injury.
- claim_ids: c27
- hash: `3e42ffedd1ae08a2`

## Provenance (21 model passes)
- chain valid: yes · head: `9dd84a8f41479ef5`

- repair · system/audit-repair · 2026-06-29T13:24 · hash `ea74e234733c`
- collaborate · gemini/gemini-2.5-flash · 2026-06-29T14:49 · hash `98b94bd5887e`
- synthesize_body · grok/grok-4.3 · 2026-06-29T14:50 · hash `8936a232a0eb`
- repair · repair · 2026-06-29T19:42 · hash `abe265f0e2b8`
- claim · fill-slots · 2026-06-29T20:56 · hash `ccd6073b59ab`
- claim · fill-slots · 2026-06-29T20:56 · hash `60b23d4855b8`
- sources · grok-4.3 · 2026-06-29T21:28 · hash `a90798ca44af`
- voxel_divide · owner · 2026-07-17T02:38 · hash `9dd84a8f4147`

## Question graph
- questions: 0 · evidence ingests: 3

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ara-290-carpal-tunnel","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ara-290-carpal-tunnel|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ara-290-carpal-tunnel|tier|assertion`
- **iMessage ask:** `ara-290-carpal-tunnel|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ara-290-carpal-tunnel`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*